TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY)

Overview

TC Biopharm (Holdings) Plc is a pioneering clinical-stage biopharmaceutical enterprise that dedicates its efforts towards the advancement of immunotherapy products. This innovative endeavor is primarily anchored on its proprietary allogeneic gamma delta T cell platform. Having been established in the year 2013, the company proudly situates its headquarters in Motherwell, the United Kingdom, marking a significant presence in the realm of biopharmaceutical research with a clear focus on harnessing the potential of immunotherapies to address critical medical conditions.

Products and Services

• OmnImmune

  An advanced allogeneic unmodified gamma-delta T cell therapy product, OmnImmune is at the forefront of TC Biopharm's product pipeline. Currently under rigorous Phase 2/3 trials, this groundbreaking treatment is designed to combat acute myeloid leukemia—a formidable form of cancer affecting the blood and bone marrow. OmnImmune exemplifies the company's commitment to leveraging the power of gamma delta T cells in developing effective cancer treatments.

• ImmuniStim

  ImmuniStim stands as another pillar of TC Biopharm's innovative product range, focusing on the utilization of unmodified cell therapy. This versatile treatment is aimed at addressing not only viral infections but also a variety of cancers, highlighting the adaptable nature of the company's immunotherapy approach. Through ImmuniStim, TC Biopharm seeks to pioneer new frontiers in the fight against cancers and infections by harnessing the body's own immune system.